Latest News for: b-cell lymphomas

Edit

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

Pharmiweb 27 Jan 2025
OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation ...
Edit

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Pharmiweb 27 Jan 2025
Primary Mediastinal Large B-Cell Lymphoma. KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
Edit

The CGT rush for new cures

Business Line 26 Jan 2025
Earlier this month, Immuneel rolled out its first internationally benchmarked CAR-T product for adult B-cell non-Hodgkin lymphoma (B-NHL).
Edit

‘Really tough days’: Dave Coulier’s wife gives update on his cancer treatments

WPXI 25 Jan 2025
“My doctors called me back and they said, ‘We wish we had better news for you, but you have non-Hodgkin’s lymphoma and it’s called B cell and it’s very aggressive,’” he said in November.‘Full House...
Edit

Surgeon General’s advisory sparks a conversation about alcohol, cancer and health

The Oregonian 25 Jan 2025
The researchers reported that they “consistently observed” an inverse association of alcohol with both Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ... They project approximately 13,000 deaths from renal cell cancer, the most common form of kidney cancer.
Edit

Dave Coulier’s Wife Shares Update On His ‘Difficult’ Cancer Treatment

Knoxville Daily Sun 24 Jan 2025
Three days later, my doctors called me back, and they said, ‘We wish we had better news for you, but you have non-Hodgkin’s lymphoma and it’s called B cell and it’s very aggressive,’” Coulier told People.
Edit

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva� in China as Second-line Treatment

Antara News 22 Jan 2025
Being the first product of JW Therapeutics, Carteyva� has been approved by NMPA for three indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r ...
Edit

Delhi's air quality remains 'poor', foggy weather disrupts trains, flights

International Business Times 22 Jan 2025
Delhi's air quality remains in the 'poor' category for the second consecutive day this week, with an Air Quality Index (AQI) of 264 recorded at 6 a.m ... Also Read ... Delhi ... Immuneel launches affordable CAR T-cell therapy for non-Hodgkin's Lymphoma in India.
Edit

Catalent Announces Collaboration with Galapagos to Further Expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S.

Pharmiweb 21 Jan 2025
and Europe, to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications.
Edit

Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is ...

GetNews 21 Jan 2025
Venetoclax by Abbvie is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 (BCL-2) protein ... The B-cell leukemia/lymphoma-2 (BCL-2) inhibitor, venetoclax ...
Edit

Delhi wakes up to 'poor' air quality as cloudy skies persist

International Business Times 21 Jan 2025
Delhi woke up to poor air quality on Tuesday, with the Air Quality Index (AQI) recorded at 319 at 6 a.m., according to the Central Pollution Control Board (CPCB) ... Immuneel launches affordable CAR T-cell therapy for non-Hodgkin's Lymphoma in India ... .
Edit

Minimum temperature rises above freezing point in J&K;'s Srinagar

International Business Times 21 Jan 2025
2For the first time after December 3, 2024, the minimum temperature rose above the freezing point in Srinagar on Tuesday while Jammu city weather improved ... Also Read ... Immuneel launches affordable CAR T-cell therapy for non-Hodgkin's Lymphoma in India. .
Edit

Immuneel launches affordable CAR T-cell therapy for non-Hodgkin's Lymphoma in India

International Business Times 20 Jan 2025
Bengaluru-based cell and gene therapy start-up Immuneel Therapeutics on Monday announced the launch of Qartemi -- the country's first personalised and precision therapy CAR T-cell therapy for treating B-cell Non-Hodgkin Lymphoma (B-NHL) in adults.
Edit

Bengaluru company launches low-cost treatment for blood cancer

The Economic Times 19 Jan 2025
... cell therapy, to treat B-cell Non-Hodgkin Lymphoma.

Most Viewed

×